UK cost watch­dog drafts guid­ance against 5 Covid treat­ments and J&J de­pres­sion med

It looks like five Covid treat­ments like­ly won’t make the NICE list this year, the UK’s cost-ef­fec­tive­ness watch­dog re­cent­ly an­nounced, and nei­ther will J&J’s es­ke­t­a­mine.

The coun­try’s Na­tion­al In­sti­tute for Health and Care Ex­cel­lence, which ad­vis­es the Na­tion­al Health Ser­vice, re­leased draft guid­ance on Wednes­day that rec­om­mends against Re­gen­eron’s mon­o­clon­al an­ti­body com­bo Re­gen-Cov (al­so known as casiriv­imab and imde­vimab), GSK’s Xe­vudy (sotro­vimab), and As­traZeneca’s Evusheld (tix­agevimab and cil­gav­imab) due to un­cer­tain­ty over just how ef­fec­tive they are against Omi­cron.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER